Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03818542 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03818542 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 3 participants.
The verdict
NCT03818542, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
A study evaluating the safety, pharmacokinetics, and biomarker profiles of multiple study drugs as monotherapy in subjects with newly diagnosed, treatment-naïve locally advanced squamous cell carcinoma of the head and neck who are candidates for surgical resection.
Interventions
- DRUG ABBV-927
- DRUG ABBV-181
- DRUG ABBV-368
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2020-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03818542
The ClinicalTrials.gov registry entry for NCT03818542 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which ABBV-927 is the first listed.
NCT03818542 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03818542 about?
NCT03818542 is a clinical study titled "A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma". A study evaluating the safety, pharmacokinetics, and biomarker profiles of multiple study drugs as monotherapy in subjects with newly diagnosed, treatment-naïve locally advanced squamous cell carcinoma of the head and neck who are candidates for surgical resection.
What is the current status of trial NCT03818542?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-01-22. Estimated completion is 2020-09-23.
What interventions are being tested in trial NCT03818542?
The interventions under investigation include: ABBV-927 (DRUG), ABBV-181 (DRUG), ABBV-368 (DRUG).
Who is sponsoring clinical trial NCT03818542?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.